

Program Resource Guide

# What Is Shared Decision-Making?

**Shared Decision-Making (SDM):** Process of communication by which patients and clinicians collaborate to make healthcare decisions. The process encourages patients to take a more active role in their care and treatment.

#### Factors to Consider When Choosing Treatment

#### Disease-related factors:

- What does the leukemia look like?
- What are the blasts like?
- What are the mutations or chromosomal abnormalities?

### Patient-related factors:

- Age
- Overall health of patient
- Patient lifestyle and preferences

# **Testing for Personalized AML Care**

**Cytogenetic analysis (Karyotyping)**: Testing of blood, bone marrow, or tissue in order to identify changes in chromosomes.

**Immunophenotyping**: Test using antibodies to identify cells based on the markers or antigens present on the cell's surface.

**Fluorescence in Situ Hybridization (FISH)**: A chromosome test used to identify specific genes or chromosome changes.

**Next-generation sequencing (NGS)**: Technology to sequence DNA or RNA to identify genetic variations associated with diseases or other biological phenomena.

**Complex Karyotype (CK)**: A classification of cytogenetic risks associated with a poor prognosis. In AML, a CK classification is the presence of three or more chromosomal abnormalities.

Inhibitor Therapy	7 + 3 Regimen	
<ul> <li>IDH Inhibitors <ul> <li>Enasidenib (Idhifa)</li> <li>Ivosidenib (Tibsovo)</li> </ul> </li> <li>FLT3 Inhibitors <ul> <li>Midostaurin (Rydapt)</li> <li>Gilteritinib (Xospata)</li> <li>Sorafenib (Nexavar)</li> </ul> </li> <li>Venetoclax (Venclexta): Inhibitor therapy that targets the Bcl-2 protein.</li> </ul>	Intensive chemotherapy that consists of getting 7 continuous days of a single treatment, along with short infusions of a second treatment during the first 3 days.	
	Hypomethylating Agents (HMAs)	
	<ul><li>Decitabine (Dacogen)</li><li>Azacitidine (Vidaza)</li></ul>	
Menin Inhibitors		

A novel class of targeted therapies showing promise in the treatment of acute leukemias with the NPM1 mutation or the KMT2A mutation.

# EXPERT ADVICE FOR NAVIGATING AML TREATMENT AND CARE DECISIONS



Program Resource Guide

### Glossary

**Aspirate:** Withdrawing fluid, tissue, or other substance from the body for further examination of a disease or condition.

**Biobanking**: The process by which samples of bodily fluid or tissue are collected for research use to improve our understanding of health and disease.

**Bone marrow biopsy:** Procedure that involves collecting a small sample of bone marrow, usually from the hip bone, in order to be examined by a laboratory. This procedure is used to confirm a diagnosis and may be used to monitor the disease over time.

**CAR (Chimeric Antigen Receptor) T-cell therapy**: A treatment in which the T cells (a type of immune system cell) of a patient are laboratory-altered to attack cancer cells in the body. **Genetic testing (molecular profiling or biomarker testing):** Laboratory testing that identifies certain gene mutations, proteins, chromosomal abnormalities and/or other molecular changes that are unique to an individual's disease. In cancer, it may be used to evaluate treatment or to make a prognosis.

**Magrolimab:** Monoclonal antibody targeting CD47 that is being studied in AML patients. **Maintenance therapy:** Refers to treatment given to patients after initial therapy that is meant to maintain a remission or prevent return of the disease.

**Monoclonal antibodies (mAb)**: Proteins made in a laboratory meant to stimulate your immune system to fight a particular disease or infection.

**Stem cell transplant:** A procedure, also called a bone marrow transplant, in which healthy blood stem cells are used to replace damaged or diseased bone marrow. This procedure can be used to treat certain types of blood cancers.

**Standard of care:** An established guideline that is consensus among experts as the most appropriate and/or effective treatment for a specific type and stage of cancer.

Visit Our Program Partners	Insist! AML
CancerGRACE	👳 👰 📮 🛛 Insist! AML is brought to you by
CURE	<b>INSIST!</b> the Patient Empowerment
<ul> <li>MyHealthTeam</li> </ul>	Network. It is made possible through support from Astellas,
Leukemia Research Foundation	Bristol Myers Squibb, Foundation Medicine, and
<ul> <li>The Leukemia &amp; Lymphoma Society (LLS)</li> </ul>	generous donations from people like you.
question@powerfulpatients.org	werfulpatients.org